Literature DB >> 19052882

Metalloproteinases 2 and 9 activity during promotion and progression stages of rat liver carcinogenesis.

Kelly Silva Furtado1, Paulo Wagner Pires, Luis Antonio Justulin, Maria Aparecida Marchesan Rodrigues, Sergio Luis Felisbino, Luis Fernando Barbisan.   

Abstract

Activity of metalloproteinases 2 and 9 (MMP-2 and 9) during promotion and progression of rat liver carcinogenesis was investigated in a modified resistant hepatocyte model. Development of preneoplastic liver lesions positive for glutathione S-transferase 7-7-(GST-P 7-7-positive PNL) and tumors besides hepatocytes positive for proliferating cell nuclear antigen (PCNA) were quantified and compared to MMP-2 and-9 activity using gelatin zymography. Marked increases in GST-P 7-7-positive PNL development, PCNA labeling indices, MMP-2 (pro, intermediate and active forms) and pro-MMP-9 activity were observed after proliferative stimulus induced by 2-acetylaminofluorene (2-AAF) exposure cycles. After 2-AAF withdrawal, increase in MMP-2 activity was detected only in neoplastic mixed lesions, whereas active MMP-9 was increased in both PLN and neoplastic tissues. Our findings suggest that MMP-2 may be associated with proliferative events induced by 2-AAF rather than with selective growth of PNL and that MMP-9 could be associated with progression of PNL and neoplastic mixed lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19052882     DOI: 10.1007/s10735-008-9206-x

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  35 in total

Review 1.  Pathways of progression in hepatocarcinogenesis.

Authors:  H C Pitot
Journal:  Lancet       Date:  2001-09-15       Impact factor: 79.321

2.  Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat.

Authors:  T Knittel; M Mehde; A Grundmann; B Saile; J G Scharf; G Ramadori
Journal:  Histochem Cell Biol       Date:  2000-06       Impact factor: 4.304

3.  Actual invasive potential of human hepatocellular carcinoma revealed by in situ gelatin zymography.

Authors:  T Kaneyoshi; H Nakatsukasa; T Higashi; K Fujiwara; I Naito; K Nouso; K Kariyama; Y Kobayashi; M Uemura; S I Nakamura; Y Iwasaki; T Tsuji
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

Review 4.  The hepatic extracellular matrix. I. Components and distribution in normal liver.

Authors:  A Martinez-Hernandez; P S Amenta
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 5.  Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma.

Authors:  S Sell; H A Dunsford
Journal:  Am J Pathol       Date:  1989-06       Impact factor: 4.307

6.  Dose-dependent effects of 2-acetylaminofluorene on hepatic foci development and cell proliferation in rats.

Authors:  D Tiwawech; R Hasegawa; Y Kurata; M Tatematsu; M A Shibata; W Thamavit; N Ito
Journal:  Carcinogenesis       Date:  1991-06       Impact factor: 4.944

Review 7.  Preneoplastic lesions in human hepatocarcinogenesis.

Authors:  Louis Libbrecht; Valeer Desmet; Tania Roskams
Journal:  Liver Int       Date:  2005-02       Impact factor: 5.828

8.  Quantitative and/or qualitative changes in the p21-H-ras post-translational products in regenerating liver and during hepatocarcinogenesis.

Authors:  B Gulbis; K Alexandre; P Galand
Journal:  Int J Cancer       Date:  1993-11-11       Impact factor: 7.396

9.  Advantages and limitations of stereological estimation of placental glutathione S-transferase-positive rat liver cell foci by computerized three-dimensional reconstruction.

Authors:  K Imaida; M Tatematsu; T Kato; H Tsuda; N Ito
Journal:  Jpn J Cancer Res       Date:  1989-04

10.  Strain differences in susceptibility to 2-acetylaminofluorene and phenobarbital promotion of rat hepatocarcinogenesis in a medium-term assay system: quantitation of glutathione S-transferase P-positive foci development.

Authors:  M Asamoto; H Tsuda; M Kagawa; J L de Camargo; N Ito; S Nagase
Journal:  Jpn J Cancer Res       Date:  1989-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.